Skip to content

The Colchicine heart failure preserved trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506207-26-00
Enrollment
152
Registered
2023-09-27
Start date
2024-01-18
Completion date
Unknown
Last updated
2024-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction (HFpEF)

Brief summary

To investigate the effect of colchicine, as compared with placebo, on heart failure related health status using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS)

Detailed description

To investigate the effect of colchicine, as compared to placebo, on heart failure related health status using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS)., To investigate the effect of colchicine on the proportion of patients with a ≥ 5-point increase in KCCQ-CS and KCCQ-OS compared to placebo

Interventions

Sponsors

Gentofte Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
To investigate the effect of colchicine, as compared with placebo, on heart failure related health status using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS)

Secondary

MeasureTime frame
To investigate the effect of colchicine, as compared to placebo, on heart failure related health status using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS)., To investigate the effect of colchicine on the proportion of patients with a ≥ 5-point increase in KCCQ-CS and KCCQ-OS compared to placebo

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026